HIV

Optimized M24B Aminopeptidase Inhibitors for CARD8 Inflammasome Activation

34 views | Jan 07 2024

The development of CQ80 as a selective dual inhibitor of PEPD and XPNPEP1 presents a promising avenue to selectively activate the CARD8 inflammasome, offering a potent tool for studying its biology and therapeutic potential in inflammation-related conditions. [Read the Full Post]

Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study

57 views | Aug 08 2023

The combination therapy of tropifexor (TXR) and cenicriviroc (CVC) did not show significant additional efficacy compared to respective monotherapies in terms of alanine aminotransferase (ALT) levels, body weight, or histological endpoints in the treatment of non-alcoholic steatohepatitis (NASH) in a phase 2b study. [Read the Full Post]

C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape

37 views | Aug 08 2023

Cenicriviroc (CVC) treatment and CCR2 deletion alleviate liver fibrosis by restoring the immune cell landscape, inhibiting the hepatic accumulation of inflammatory macrophages and neutrophils, and suppressing profibrotic gene transcription through inactivation of the CCR2-STAT1/NFκB/ERK signaling pathways. [Read the Full Post]

AMD3100-mediated CXCR4 inhibition impairs development of primary lymphoma of the central nervous system

134 views | Jul 13 2023

The inhibition of CXCR4-CXCL12 interactions by AMD3100 in primary lymphoma of the central nervous system (PCNSL) downregulates CD200 expression in lymphoma cells, leading to increased microglial activation, impaired lymphoma cell invasion, and reduced tumor size, suggesting the potential therapeutic utility of AMD3100 in PCNSL. [Read the Full Post]

Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients

64 views | Jul 13 2023

The retrospective analysis suggests that chemo-mobilization with etoposide, cytarabine, and pegfilgrastim is a highly effective and tolerable strategy for mobilizing hematopoietic stem cells in poorly mobilizing patients with multiple myeloma (MM) or lymphoma. [Read the Full Post]

SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling

33 views | May 18 2023

The combination of SMAC mimetics and HDAC inhibitors shows remarkable synergy in suppressing IAP proteins and restoring apoptotic pathways, providing a potential therapeutic strategy for recurrent ovarian cancer. [Read the Full Post]

The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study

68 views | Apr 18 2023

The study found that pentosan polysulfate sodium (PPS) has promising effects on improving dyslipidemia and providing symptomatic pain relief in people with knee osteoarthritis (OA), but further studies with larger sample sizes and more rigorous study designs are needed to confirm these findings. [Read the Full Post]

TGFβ1+CCR5+ neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice

43 views | Mar 12 2023

The study suggests that reducing the numbers of TGFβ1+CCR5+ neutrophils in the bone marrow, potentially through the use of a CCR5 antagonist like maraviroc, could be a treatment for age-related osteoporosis. [Read the Full Post]

Multivariate Chemometric Comparison of Forced Degradation and Electrochemical Oxidation LC-MS Profiles of Maraviroc

74 views | Mar 12 2023

The study found that maraviroc is susceptible to UVA, H2O2, and electrochemical degradation, and suggests that electrochemical methods can be used as a supplement to forced degradation procedures for a quicker and relatively low-cost alternative. [Read the Full Post]

DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065)

49 views | Mar 10 2023

The study found that combination chemotherapy regimens can improve response rates and survival times in patients with metastatic malignant melanoma, but careful monitoring of toxicity is necessary and treatment decisions should be individualized based on the patient's clinical profile. [Read the Full Post]